[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes
Not Applicable
Completed
- Conditions
- Type2 Diabetes
- Interventions
- Radiation: Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan
- Registration Number
- NCT02967354
- Lead Sponsor
- Per-Ola Carlsson
- Brief Summary
Cross-sectional study to investigate subjects at different stages of type 2 diabetes development with expected stratification of pancreatic islet mass. Non-diabetic individuals were assigned as control. The primary outcome was the \[11C\]5-hydroxy-tryptophan uptake and retention in the pancreas as a surrogate marker for the endogenous islet mass.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
- Type 2 diabetes fulfilling criteria for the four different study groups, or healthy volunteers
Exclusion Criteria
- Ongoing pregnancy
- Renal failure (GFR<60 ml/min)
- Magnetic metal parts in the body
- Ongoing treatment with selective serotonin receptor inhibitors
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Obese with oral antidiabetic drugs Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan BMI\>30, Type 2 diabetes treated with oral antidiabetic drugs Obese, treated with oral antidiabetic drugs + insulin Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan BMI\>30, Type 2 diabetes treated with oral antidiabetic drugs + insulin Normal weight, treated with oral antidiabetic drugs Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs Normal weight, treated with oral antidiabetic drugs + insulin Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan BMI 20-26. Type 2 diabetes treated with oral antidiabetic drugs + insulin Healthy control Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan Healthy control
- Primary Outcome Measures
Name Time Method [11C]5-hydroxy-tryptophan Uptake in the Pancreas Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release Uptake of tracer with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release
- Secondary Outcome Measures
Name Time Method Pancreatic Volume Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release Pancreatic Fat Content Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release Hepatic Fat Content Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release Pancreatic Perfusion Within two weeks after functional measurement with glucose potentiated arginine stimulation of insulin release Uptake of radioactive water with correlation to functional measurement with glucose-potentiated arginine stimulation of insulin release